Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment

References

• Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 56(25), e50–e103 (2010).
   Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115, 949–952 (2007).
   Google Scholar
• PO Kwiterovich Jr. Lipid, apolipoprotein and lipoprotein metabolism: implications for the diagnosis and treatment of dyslipidemia. In: The Johns Hopkins Textbook of Dyslipidemia. Kwiterovich PO Jr (Ed.). Lippincott Williams and Wilkins, PA, USA, 1–21 (2009).
   Google Scholar
• Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J. Intern. Med. 255(2), 188–205 (2004).
   Google Scholar
• Sniderman AD, de Graaf J, Couture P. ApoB and the atherogenic apoB dyslipoproteinemias. In: The Johns Hopkins Textbook of Dyslipidemia. Kwiterovich PO Jr (Ed.). Lippincott Williams and Wilkins, PA, USA, 196–210 (2009).
   Google Scholar
• Davidson MH, Ballantyne CM, Jacobson TA et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5(5), 338–367 (2011). ▪▪ Overview by an expert panel of lipidologists on the use of biomarkers in initial coronary heart disease (CHD) risk prediction and on-treatment management decisions.
   Google Scholar
• Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54(23), 2129–2138 (2009).
   Google Scholar
• Tabas I. Subendotheilal lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832–1844 (2007).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
   Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24(11), 987–1003 (2003).
   Google Scholar
• Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM). Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 96, 2128–2136 (1997).
   Google Scholar
• Paul S. Bachorik. Measurement of lipids, lipoproteins and apolipoproteins. In: The Johns Hopkins Textbook of Dyslipidemia. Kwiterovich PO Jr (Ed.). Lippincott Williams & Wilkins, PA, USA, 22–37 (2009).
   Google Scholar
• Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J. Am. Coll. Cardiol. 58(5), 457–463 (2011).
   Google Scholar
• Sniderman AD, St-Pierre A, Cantin B. Concordance/discordance between plasma apoliporotein B levels and the cholesterol indexes of atherosclerotic risk. Am. J. Cardiol. 91, 1173–1177 (2003).
   Google Scholar
• Sniderman AD, Williams K, de Graaf J. Non-HDL-C equals apolipoprotein B: except when it does not! Curr. Opin. Lipidol. 21, 518–524 (2010).
   Google Scholar
• Baruch L, Agarwahl S, Gupta B et al. Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein? J. Clin. Lipidol. 4, 259–264 (2010).
   Google Scholar
• Cooper G, Smith S, Myers G. Estimating and minimizing effects of biologic sources of variation by relative range when measuring the mean of serum lipids and lipoproteins. Clin. Chem. 42, 732–737 (1994).
   Google Scholar
• Schectman G, Patsches M, Sasse E. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin. Chem. 42, 732–737 (1996).
   Google Scholar
• Bachorik P, Ross J. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin. Chem. 41, 1414–1420 (1995).
   Google Scholar
• Sniderman A, McQueen M, Contois J, Williams K, Furberg CD. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J. Clin. Lipidol. 4(3), 152–155 (2010).
   Google Scholar
• Contois JH, Warnick GR, Sniderman AD. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J. Clin. Lipidol. 5, 264–272 (2011). ▪ Reviews the pitfalls in the interpretation of reported lipid and lipoprotein measurements.
   Google Scholar
• Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am. J. Cardiol. 90(8A), i22–i29 (2002).
   Google Scholar
• Mudd JO, Borlaug BA, Johnston PV et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J. Am. Coll. Cardiol. 50(18), 1735–1741 (2007).
   Google Scholar
• Rainwater DL, McMahan CA, Malcom GT et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. Arterioscler. Thromb. Vasc. Biol. 19, 753–761 (1999).
   Google Scholar
• The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. JAMA 302, 1993–2000 (2009). ▪▪ Meta-analysis examining the value of measurement of lipids versus apolipoprotein biomarkers for CHD risk prediction, concluding that apolipoprotein measurement does not add to the information provided by lipid measurement.
   Google Scholar
• Sniderman AD, Williams K, Contois JH et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4(3), 337–345 (2011). ▪▪ Meta-analysis challenging the conclusions of the Emerging Risk Factors Collaboration Study and making a case for the importance of ApoB measurement in initial CHD risk assessment.
   Google Scholar
• Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-HDL-C reduction and CHD risk. J. Am. Coll. Cardiol. 53, 316–322 (2009). ▪ Meta-analysis demonstrating the relationship between non-HDL cholesterol lowering and reduction in CHD risk in patients treated with a variety of pharmacologic and nonpharmacologic interventions.
   Google Scholar
• Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161, 1413–1419 (2001).
   Google Scholar
• Arsenault BJ, Rana JS, Stroes ES et al. Beyond low density lipoprotein cholesterol: respective contributions of non-HDL-C levels, triglycerides and total/HDL ratio to CHD risk in apparently healthy men and women. J. Am. Coll. Cardiol. 55, 35–41 (2009).
   Google Scholar
• Bittner VA. Non-HDL-C levels predict five year outcomes in the BARI. Circulation 106, 2537–2542 (2002).
   Google Scholar
• Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307(12), 1302–1309 (2012). ▪ Meta-analysis demonstrating the value of non-HDL cholesterol measurement in the prediction of CHD events in statin-treated patients.
   Google Scholar
• Mora S, Glynn R. On-treatment non-HDL-C, apoB, triglycerides, and lipid ratios in relation to vascular risk after treatment with potent statin therapy. J. Am. Coll. Cardiol. 59, 1521–1528 (2012).
   Google Scholar
• Robinson JG, Wang S. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus LDL-C and non-HDL-C for cardiovascular risk reduction in randomized trials. Am. J. Cardiol. 110(10), 1468–1476 (2012).
   Google Scholar
• Parish S, Offer A, Clarke R et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125(20), 2469–2478 (2012).
   Google Scholar
• Virani SS. Barriers to non-HDL cholesterol goal attainment by providers. Am. J. Med. 124, 876–880 (2011).
   Google Scholar
• Cromwell WC. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study. J. Clin. Lipidol. 1, 583–592 (2007).
   Google Scholar
• Otvos JD, Mora S. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 5, 205–213 (2011).
   Google Scholar
• Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 225, 444–449 (2012).
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk. Diabetes Care 31, 811–822 (2008).
   Google Scholar
• Malave H, Castro M. Evaluation of LDL-P distribution in patients with Type 2 diabetes with LDL-C <50 mg/dl and non-HDL-C <80 mg/dl. Am. J. Cardiol. 110, 662–665 (2012).
   Google Scholar
• Di Angelantonio E, Gao P, Pennells L et al.; The Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 307, 2499–2506 (2012). ▪ Meta-analysis calling into question the value of employing ApoB measurement in addition to standard risk factors for cardiovascular disease risk reclassification or for statin-treatment decisions in intermediate-risk populations.
   Google Scholar